CNS Market Overview - Commercial dynamics and outlook of the neurology and pain
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
When comparing the three CNS sectors the pain sector is by far the largest by volume prescriptions, accounting for 53.5% of the 2007 CNS market total. However, in terms of value, psychiatry is the dominant sector, accounting for over 48% of total CNS sales, whereas neurology is the fastest growing sector.
On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer’s disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.
Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.
Register yourself to FarmavitaR+ and post your PR, professional articles, comments about articles. Participate in discussions at message board and network with other pharmaceutical professionals.
FarmavitaR+ Journal 
